SMP-100
IND- Indications
- IBS-D, IBS-M
Company intelligence / Profile preview
SciMount Pharmatech, Co. Ltd.
Chengdu, Sichuan Sheng, Chinaprnewswire.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SciMount has received FDA approval for SMP-100's IND application for the treatment of Irritable Bowel Syndrome with diarrhea. The company is conducting a randomized, double-blinded, placebo-controlled Phase I clinical trial investigating safety and pharmacokinetics after oral administration in healthy volunteers.
- Therapeutic areas
- GastroenterologyOncologyOphthalmology
- Modalities
- Small moleculesADC therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on SciMount Pharmatech, Co. Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SciMount Pharmatech, Co. Ltd..